Trastuzumab: Anti-HER2 antibody for treatment of metastatic breast cancer

被引：13

作者：

Wong, WM ^{[1
]}

机构：

[1] Univ Calif Irvine, Med Ctr, Pharmaceut Serv, Orange, CA 92717 USA

来源：

CANCER PRACTICE | 1999年 / 7卷 / 01期

关键词：

D O I：

10.1046/j.1523-5394.1999.07108.x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：48 / 50

页数：3

共 12 条

[1] Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast
Baselga, J
Tripathy, D
Mendelsohn, J
Baughman, S
Benz, CC
Dantis, L
Sklarin, NT
Seidman, AD
Hudis, CA
Moore, J
Rosen, PP
Twaddell, T
Henderson, IC
Norton, L
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) : 737 - 744
[2] HUMANIZATION OF AN ANTI-P185HER2 ANTIBODY FOR HUMAN CANCER-THERAPY
CARTER, P
PRESTA, L
GORMAN, CM
RIDGWAY, JBB
HENNER, D
WONG, WLT
ROWLAND, AM
KOTTS, C
CARVER, ME
SHEPARD, HM
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (10) : 4285 - 4289
[3] COBLEIGH MA, 1998, P AN M AM SOC CLIN, V17, pA97
[4] DICKSON RB, 1997, CANC PRINCIPLES PRAC, P1551
[5] DREBIN JA, 1988, ONCOGENE, V2, P273
[6] *GEN INC, 1998, HERC PACK INS
[7] Harris Jay, 1997, P1557
[8] Herceptin raises its sights beyond advanced breast cancer
McNeil, C
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (12) : 882 - 883
[9] Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
Pegram, MD
Lipton, A
Hayes, DF
Weber, BL
Baselga, JM
Tripathy, D
Baly, D
Baughman, SA
Twaddell, T
Glaspy, JA
Slamon, DJ
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) : 2659 - 2671
[10] MONOCLONAL-ANTIBODY THERAPY OF HUMAN CANCER - TAKING THE HER2 PROTOONCOGENE TO THE CLINIC
SHEPARD, HM
LEWIS, GD
SARUP, JC
FENDLY, BM
MANEVAL, D
MORDENTI, J
FIGARI, I
KOTTS, CE
PALLADINO, MA
ULLRICH, A
SLAMON, D
[J]. JOURNAL OF CLINICAL IMMUNOLOGY, 1991, 11 (03) : 117 - 127

← 1 2 →